AIMD Stock Price (-0.04) | Stock Quote, Chart & News for Amarillo Biosciences Inc. on Fox Business

Open $1.99	Day Range 1.72 - 2.07
52 Week Range 1.61 - 4.50	Market Cap $14.24M
Shares Outstanding 6.98M	Public Float 2.74M
Beta 2.49	Rev. Per Employee N/A
P/E Ratio N/A	EPS -$4.18
Yield 0.00%	Dividend N/A
EX-DIVIDEND DATE	SHORT INTEREST N/A
AVERAGE VOLUME 1.73M

About amarillo biosciences inc. - AIMD

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

AIMD At a Glance

Ainos, Inc.

8880 Rio San Diego Drive

San Diego, California 92108

Phone	1-858-869-2986	Revenue	20.73K
Industry	Information Technology Services	Net Income	-14,863,161.00
Sector	Technology Services	Employees	44
Fiscal Year-end	12 / 2025
View SEC Filings

AIMD Valuation

P/E Current	N/A
P/E Ratio (with extraordinary items)	N/A
P/E Ratio (without extraordinary items)	N/A
Price to Sales Ratio	209.062
Price to Book Ratio	0.453
Price to Cash Flow Ratio	N/A
Enterprise Value to EBITDA	-1.376
Enterprise Value to Sales	600.161
Total Debt to Enterprise Value	0.965

AIMD Efficiency

Revenue/Employee	471.114
Income Per Employee	-337,799.114
Receivables Turnover	370.161
Total Asset Turnover	0.001

AIMD Liquidity

Current Ratio	1.097
Quick Ratio	1.06
Cash Ratio	0.984

AIMD Profitability

Gross Margin	-23,317.97
Operating Margin	-66,772.155
Pretax Margin	-71,698.398
Net Margin	-71,702.258
Return on Assets	-49.003
Return on Equity	-74.383
Return on Total Capital	-54.016
Return on Invested Capital	-54.161

AIMD Capital Structure

Total Debt to Total Equity	77.338
Total Debt to Total Capital	43.61
Total Debt to Total Assets	41.637
Long-Term Debt to Equity	58.003
Long-Term Debt to Total Capital	32.708

Income Statement
Balance Sheet
Cash Flow Statement

Annual Financials for Amarillo Biosciences Inc. - AIMD

Collapse All in section

All values USD millions.	2021	2022	2023	2024	5-year trend
Sales/Revenue	594.56K	3.52M	122.11K	20.73K
Sales Growth	+3,489.71%	+491.97%	-96.53%	-83.02%
Cost of Goods Sold (COGS) incl D&A	2.22M	6.93M	5.23M	4.85M
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	2.03M	4.81M	4.85M	4.80M
Depreciation	31.39K	291.71K	328.94K	252.55K
Amortization of Intangibles	2.00M	4.52M	4.52M	4.55M
COGS Growth	+8,430.81%	+212.65%	-24.53%	-7.15%
Gross Income	(1.62M)	(3.41M)	(5.11M)	(4.83M)
Gross Income Growth	-17,126.04%	-110.22%	-49.81%	+5.34%
Gross Profit Margin	-272.69%	-96.84%	-4,181.56%	-23,317.97%

	2021	2022	2023	2024	5-year trend
SG&A Expense	2.25M	10.57M	7.81M	9.01M
Research & Development	1.92M	2.03M	7.03M	8.41M
Other SG&A	325.47K	8.54M	782.82K	593.70K
SGA Growth	+56.96%	+370.50%	-26.06%	+15.28%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	718.21K	583.96K	-
EBIT after Unusual Expense	(3.87M)	(13.98M)	(13.64M)	(14.43M)
Non Operating Income/Expense	(2.55K)	23.05K	12.28K	179.27K
Non-Operating Interest Income	-	-	-	-	-
Equity in Earnings of Affiliates	-	-	-	-	-
Interest Expense	18.69K	53.53K	144.19K	616.47K
Interest Expense Growth	+83.44%	+186.41%	+169.38%	+327.53%
Gross Interest Expense	18.69K	53.53K	144.19K	616.47K
Interest Capitalized	-	-	-	-	-
Pretax Income	(3.89M)	(14.01M)	(13.77M)	(14.86M)
Pretax Income Growth	-168.07%	-260.19%	+1.69%	-7.93%
Pretax Margin	-654.04%	-397.96%	-11,276.33%	-71,698.40%
Income Tax	-	-	800	800	-
Income Tax - Current - Domestic	-	-	(1.57M)	(128.20K)	-
Income Tax - Current - Foreign	-	-	-	-	-
Income Tax - Deferred - Domestic	-	-	1.57M	129.00K	-
Income Tax - Deferred - Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Earnings of Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(3.89M)	(14.01M)	(13.77M)	(14.86M)
Minority Interest Expense	-	-	-	-	-
Net Income	(3.89M)	(14.01M)	(13.77M)	(14.86M)
Net Income Growth	-168.07%	-260.19%	+1.69%	-7.93%
Net Margin Growth	-654.04%	-397.96%	-11,276.98%	-71,702.26%
Extraordinaries & Discontinued Operations	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(3.89M)	(14.01M)	(13.77M)	(14.86M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(3.89M)	(14.01M)	(13.77M)	(14.86M)
EPS (Basic)	-12.8738	-25.6772	-16.8011	-7.8198
EPS (Basic) Growth	+3.59%	-99.45%	+34.57%	+53.46%
Basic Shares Outstanding	302.05K	545.49K	819.62K	1.90M
EPS (Diluted)	-12.8738	-25.6772	-16.8011	-7.8198
EPS (Diluted) Growth	+3.59%	-99.45%	+34.57%	+53.46%
Diluted Shares Outstanding	302.05K	545.49K	819.62K	1.90M
EBITDA	(1.84M)	(9.16M)	(8.07M)	(9.04M)
EBITDA Growth	-28.76%	-399.12%	+11.95%	-12.05%
EBITDA Margin	-308.75%	-260.33%	-6,606.37%	-43,607.89%

Filing Date	Type	Category	Amended
No results

Insider Actions for Amarillo Biosciences Inc. - AIMD

Date	Name	Shares	Transaction	Value
Jan 13, 2026	Taiwan Carbon Nano Technology Corp.	1,036,356	Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.8 per share	1,865,440.80
Jan 13, 2026	Taiwan Carbon Nano Technology Corp.	1,035,925	Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.86 per share	1,926,820.50
Mar 12, 2025	Chun Hsien Tsai CEO, PRESIDENT, CHAIRMAN; Director	N/A	Conversion of derivative security	0.00
Mar 12, 2025	Yao Chung Chiang Director	206,400	Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share	94,944.00
Mar 12, 2025	Ting Chuan Lee Director	N/A	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Mar 12, 2025	Ting Chuan Lee Director	531,432	Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share	244,458.72
Mar 12, 2025	Chung Jung Tsai Director	N/A	Conversion of derivative security	0.00
Mar 12, 2025	Chung Jung Tsai Director	N/A	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Mar 12, 2025	Chung Jung Tsai Director	527,900	Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share	242,834.00
Mar 12, 2025	Chung Yi Tsai Director	N/A	Conversion of derivative security	0.00
Mar 12, 2025	Chung Yi Tsai Director	N/A	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Mar 12, 2025	Chung Yi Tsai Director	204,400	Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share	94,024.00
Mar 12, 2025	ASE Technology Holding Co., Ltd.	499,377	Open market or private purchase of non-derivative security	0.00
Mar 12, 2025	Christopher Lee CFO	N/A	Conversion of derivative security	0.00
Mar 12, 2025	Christopher Lee CFO	N/A	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Mar 12, 2025	Christopher Lee CFO	276,376	Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share	127,132.96
Mar 12, 2025	Pao Sheng Wei Director	N/A	Conversion of derivative security	0.00
Mar 12, 2025	Pao Sheng Wei Director	N/A	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Mar 12, 2025	Pao Sheng Wei Director	204,400	Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share	94,024.00
Mar 12, 2025	Yao Chung Chiang Director	N/A	Conversion of derivative security	0.00

1 Week		-4.50%
1 Month		2.69%
3 Months		-28.46%
1 Year		-38.37%
5 Years		N/A

amarillo biosciences inc. - AIMD

AIMD

Company Overview: amarillo biosciences inc. - AIMD

AIMD Key Data

AIMD Performance

AIMD Analyst Ratings